Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
Shragai T, Magen H, Lavi N, Gatt M, Trestman S, Zektser M, Ganzel C, Jarchowsky O, Berger T, Tadmor T, Leiba M, Hertzog-Tzarfaty K, Horowitz N, Shapira M, Varssano D, Berger Y, Frenkel S, Krauthammer M, Avivi I, Luttwak E, Cohen YC; Israeli myeloma study group. Shragai T, et al. Among authors: leiba m. Br J Haematol. 2023 Jan;200(1):45-53. doi: 10.1111/bjh.18479. Epub 2022 Oct 7. Br J Haematol. 2023. PMID: 36205375 Free PMC article.
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M, Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, Nagler A, Avigdor A. Leiba M, et al. Among authors: leiba r. Br J Haematol. 2014 Sep;166(5):702-10. doi: 10.1111/bjh.12946. Epub 2014 May 26. Br J Haematol. 2014. PMID: 24861981 Free article.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Dimopoulos MA, et al. N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751. N Engl J Med. 2016. PMID: 27705267 Free article. Clinical Trial.
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.
Ganzel C, Rouvio O, Avivi I, Magen H, Jarchowsky O, Herzog K, Cohen Y, Tadmor T, Horwitz NA, Leiba M, Nagler A, Cohen Y, Bulvik S, Polliack A, Rowe JM, Gatt ME; Israeli Multiple Myeloma Study Group. Ganzel C, et al. Among authors: leiba m. Leuk Res. 2018 May;68:9-14. doi: 10.1016/j.leukres.2018.02.010. Epub 2018 Mar 2. Leuk Res. 2018. PMID: 29501828
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ. Dimopoulos MA, et al. Among authors: leiba m. Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20. Haematologica. 2018. PMID: 30237262 Free PMC article. Clinical Trial.
Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
Duek A, Trakhtenbrot L, Amariglio N, Benyamini N, Zilbershats I, Ganzel C, Shevetz O, Leiba R, Rozic G, Nagler A, Leiba M. Duek A, et al. Among authors: leiba r, leiba m. Genes Chromosomes Cancer. 2019 Aug;58(8):516-520. doi: 10.1002/gcc.22738. Epub 2019 Feb 6. Genes Chromosomes Cancer. 2019. PMID: 30675954
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
Segman Y, Ribakovsky E, Avigdor A, Goldhecht Y, Vainstein V, Goldschmidt N, Harlev S, Horwitz N, Gutwein O, Gurion R, Itchaki G, Abadi U, Nemets A, Sofer O, Zektser M, Tadmor T, Dally N, Filanovsky K, Leiba M, Sarid N, Benyamini N, Herishanu Y, Ram R, Perry C, Avivi I. Segman Y, et al. Among authors: leiba m. Leuk Lymphoma. 2021 Jan;62(1):118-124. doi: 10.1080/10428194.2020.1824069. Epub 2020 Sep 27. Leuk Lymphoma. 2021. PMID: 32981410
82 results